{"id":59714,"date":"2026-03-17T14:02:41","date_gmt":"2026-03-17T06:02:41","guid":{"rendered":"https:\/\/flcube.com\/?p=59714"},"modified":"2026-03-17T14:02:42","modified_gmt":"2026-03-17T06:02:42","slug":"ascentage-pharma-and-haisco-secure-cde-spark-inclusion-for-pediatric-oncology-candidates-apg-115-and-hsk42360-target-high-unmet-need-childhood-cancers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59714","title":{"rendered":"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers"},"content":{"rendered":"\n<p>China\u2019s <strong>Center for Drug Evaluation (CDE)<\/strong> has selected two innovative oncology assets for its <strong>Support Anti\u2011tumor drugs R&amp;D for Kids (SPARK)<\/strong> initiative, accelerating development pathways for pediatric cancer therapeutics. <strong>Ascentage Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AAPG:NASDAQ\">NASDAQ: AAPG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6855:HKG\">HKG: 6855<\/a>) and <strong>Haisco Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002653:SHE\">SHE: 002653<\/a>) each received SPARK designation for distinct mechanisms targeting rare and aggressive childhood malignancies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Ascentage APG\u2011115<\/th><th>Haisco HSK42360<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>CDE (China)<\/td><td>CDE (China)<\/td><\/tr><tr><td><strong>Program<\/strong><\/td><td>SPARK (Support Anti\u2011tumor drugs R&amp;D for Kids)<\/td><td>SPARK (Support Anti\u2011tumor drugs R&amp;D for Kids)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>APG\u2011115 (oral MDM2\u2011p53 inhibitor)<\/td><td>HSK42360 tablets (BRAF V600 inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pediatric solid tumors: neuroblastoma, rhabdomyosarcoma, Ewing sarcoma<\/td><td>Pediatric recurrent\/progressive glioma with BRAF V600 mutation<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First\u2011in\u2011class MDM2\u2011p53 inhibitor with FDA ODD\/RPD<\/td><td>Brain\u2011penetrant BRAF V600 inhibitor for CNS tumors<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>FDA Orphan Drug + Rare Pediatric Disease Designation<\/td><td>Preclinical stage; China\u2011first development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-apg-115-ascentage-pharma\">APG\u2011115 (Ascentage Pharma)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Oral, highly selective <strong>MDM2\u2011p53 inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks MDM2\u2011p53 protein\u2011protein interaction, restoring p53 tumor\u2011suppressor function in p53\u2011wild\u2011type pediatric solid tumors<\/li>\n\n\n\n<li><strong>Target Cancers:<\/strong> Neuroblastoma, rhabdomyosarcoma, Ewing sarcoma \u2013 collectively representing ~15% of pediatric solid tumor mortality<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> Dual FDA designations (ODD + RPD) signal global regulatory confidence; SPARK inclusion accelerates China pivotal trial timeline<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hsk42360-haisco-pharmaceutical\">HSK42360 (Haisco Pharmaceutical)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Small\u2011molecule <strong>BRAF V600 mutation inhibitor<\/strong> with blood\u2011brain barrier penetration<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selective inhibition of oncogenic BRAF V600 signaling in glioma cells with CNS activity<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Pediatric patients with recurrent or progressive glioma harboring BRAF V600 mutation \u2013 a subset with historically poor prognosis and limited therapeutic options<\/li>\n\n\n\n<li><strong>Preclinical Profile:<\/strong> Demonstrated robust anti\u2011tumor efficacy across multiple BRAF V600\u2011mutant solid tumor models with favorable tolerability and wide therapeutic index<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-development-landscape\">Clinical &amp; Development Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Development Stage<\/th><th>Key Data<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>APG\u2011115<\/strong><\/td><td>Phase I\/II (pediatric)<\/td><td>FDA ODD\/RPD secured; mechanism validated in adult solid tumors<\/td><td>First\u2011in\u2011class potential in p53\u2011wild\u2011type pediatric cancers; global rights retained<\/td><\/tr><tr><td><strong>HSK42360<\/strong><\/td><td>Preclinical \u2192 IND\u2011enabling<\/td><td>Strong efficacy in BRAF V600 models; brain penetration confirmed<\/td><td>Addresses unmet need in pediatric CNS malignancies; differentiated from non\u2011penetrant BRAF inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric Oncology Gap:<\/strong> Childhood cancers represent &lt;1% of total oncology drug development despite being the leading disease\u2011related cause of death in children aged 1\u201114. SPARK designation provides CDE priority review, reduced data requirements, and potential conditional approval pathways.<\/li>\n\n\n\n<li><strong>APG\u2011115 Commercial Trajectory:<\/strong> Ascentage projects SPARK inclusion will compress pediatric trial timeline by 12\u201118 months. With FDA Rare Pediatric Disease Designation, APG\u2011115 qualifies for Priority Review Voucher eligibility upon approval \u2013 a transferable asset valued at $80\u2011110 million in secondary markets.<\/li>\n\n\n\n<li><strong>HSK42360 Competitive Positioning:<\/strong> BRAF V600 mutations occur in ~15\u201120% of pediatric low\u2011grade gliomas and ~5% of high\u2011grade cases. Existing BRAF inhibitors lack CNS penetration; HSK42360\u2019s brain\u2011penetrant profile addresses this pharmacological gap, positioning Haisco for potential first\u2011in\u2011class status in pediatric neuro\u2011oncology.<\/li>\n\n\n\n<li><strong>Policy Tailwinds:<\/strong> China\u2019s SPARK initiative aligns with global regulatory trends (FDA Pediatric Research Equity Act, EMA Paediatric Investigation Plans), incentivizing development in historically neglected therapeutic areas.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for APG\u2011115 and HSK42360. Actual results may differ materially due to risks including trial enrollment challenges, safety findings, regulatory requirements, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,4],"tags":[200,102,139,985,3273,24,929],"class_list":["post-59714","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","category-policy-regulatory","tag-ascentage-pharma","tag-cde","tag-haisco-pharmaceutical","tag-hkg-6855","tag-nasdaq-aapg","tag-rare-orphan-disease-drugs","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support Anti\u2011tumor drugs R&amp;D for Kids (SPARK) initiative, accelerating development pathways for pediatric cancer therapeutics. Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) and Haisco Pharmaceutical Group (SHE: 002653) each received SPARK designation for distinct mechanisms targeting rare and aggressive childhood malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59714\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support Anti\u2011tumor drugs R&amp;D for Kids (SPARK) initiative, accelerating development pathways for pediatric cancer therapeutics. Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) and Haisco Pharmaceutical Group (SHE: 002653) each received SPARK designation for distinct mechanisms targeting rare and aggressive childhood malignancies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59714\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T06:02:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T06:02:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59714#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59714\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers\",\"datePublished\":\"2026-03-17T06:02:41+00:00\",\"dateModified\":\"2026-03-17T06:02:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59714\"},\"wordCount\":572,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascentage Pharma\",\"CDE\",\"Haisco Pharmaceutical\",\"HKG: 6855\",\"NASDAQ: AAPG\",\"Rare \\\/ orphan disease drugs\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Drug\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59714#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59714\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59714\",\"name\":\"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-17T06:02:41+00:00\",\"dateModified\":\"2026-03-17T06:02:42+00:00\",\"description\":\"China\u2019s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support Anti\u2011tumor drugs R&D for Kids (SPARK) initiative, accelerating development pathways for pediatric cancer therapeutics. Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) and Haisco Pharmaceutical Group (SHE: 002653) each received SPARK designation for distinct mechanisms targeting rare and aggressive childhood malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59714#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59714\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59714#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support Anti\u2011tumor drugs R&D for Kids (SPARK) initiative, accelerating development pathways for pediatric cancer therapeutics. Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) and Haisco Pharmaceutical Group (SHE: 002653) each received SPARK designation for distinct mechanisms targeting rare and aggressive childhood malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59714","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers","og_description":"China\u2019s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support Anti\u2011tumor drugs R&D for Kids (SPARK) initiative, accelerating development pathways for pediatric cancer therapeutics. Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) and Haisco Pharmaceutical Group (SHE: 002653) each received SPARK designation for distinct mechanisms targeting rare and aggressive childhood malignancies.","og_url":"https:\/\/flcube.com\/?p=59714","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-17T06:02:41+00:00","article_modified_time":"2026-03-17T06:02:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59714#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59714"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers","datePublished":"2026-03-17T06:02:41+00:00","dateModified":"2026-03-17T06:02:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59714"},"wordCount":572,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascentage Pharma","CDE","Haisco Pharmaceutical","HKG: 6855","NASDAQ: AAPG","Rare \/ orphan disease drugs","SHE: 002653"],"articleSection":["Company","Drug","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59714#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59714","url":"https:\/\/flcube.com\/?p=59714","name":"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-17T06:02:41+00:00","dateModified":"2026-03-17T06:02:42+00:00","description":"China\u2019s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support Anti\u2011tumor drugs R&D for Kids (SPARK) initiative, accelerating development pathways for pediatric cancer therapeutics. Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) and Haisco Pharmaceutical Group (SHE: 002653) each received SPARK designation for distinct mechanisms targeting rare and aggressive childhood malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59714#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59714"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59714#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates \u2013 APG\u2011115 and HSK42360 Target High\u2011Unmet\u2011Need Childhood Cancers"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59714"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59714\/revisions"}],"predecessor-version":[{"id":59715,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59714\/revisions\/59715"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}